Newsroom

Salt Lake City – February 17, 2022 – Sera Prognostics Inc., The PregnancyCompany ®  (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced…

Salt Lake City – February 7, 2022 – Sera Prognostics Inc., The PregnancyCompany ®  (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced…

Feb 1, 2022, Sera Prognostics announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks.

Dec 15, Sera Prognostics announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).

Dec. 2, 2021, Sera Prognostics announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® Test.

Dec. 1, 2021, The newly published article presents the performance of the IBP4/SHBG biomarker pair in predicting spontaneous preterm birth (sPTB) in low and middle income geographies, with prespecified adjustment for demographic differences between the populations.

Nov. 30, 2021, Sera Prognostics announced that Sandra A. J. Lawrence has joined the Sera Board of Directors.

Nov 8,2021, Sera Prognostics announced that Zhenya Lindgardt has joined the Sera Board of Directors.

Nov. 4, 2021, Sera Prognostics announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs.

November 3, 2021, Sera Prognostics announced the publication of a rigorous  validation of a clinical decision point at spontaneous preterm birth (sPTB) risk of 15%, as determined by the company’s PreTRM® test.